589 Background: Risk factors such as hormone receptor status, primary tumor volume and grading often fail to identify node-negative breast cancer patients with poor prognosis. The search for new molecular risk markers is of primary importance in clinical practice. Changes in cell cycle control mechanisms are frequently described in human neoplasms and their prognostic significance need to be evaluated. Methods: We analysed the expression of Cyclin A in 75 consecutive node-negative breast cancer patients: 17 out of 75 (22.6%) relapsed within 5 years from diagnosis while the others did not. We correlate the expression of Cyclin A with Ki67, E2F1, tumor size, grading, estrogen receptor status (ER) and RFS (median follow-up 10 yrs). Cyclin A, Ki67 and E2F1 were determined by IHC. The median values of expression of each parameter were used as cut-off. Results: Cyclin A was overexpressed in 34 of 75 patients (45.3%) and it directly correlated with tumor size (p = 0.0009), high Ki67 (p = 0.0001) and high E2F1 (p = 0.036) levels. No relationship with age, ER status and tumor grade was observed. 12/17 pts (71%) with early relapse (within 5 yrs) showed Cyclin A overexpression in comparison with 22/58 pts (38%) who did not (p = 0.02). DFS curves for pts with Cyclin A overexpression vs no-overexpression were significantly different (p = 0.012). DFS was also different for low vs high Ki67 expression (p = 0.003) and low vs high E2F1levels (p = 0.019). Conclusions: Significantly poorer DFS was observed in cyclin A overexpressing patients. The strong relationship observed between Cyclin A overexpression, high proliferation index and large tumor size might identify breast cancers with more aggressive phenotypes and consequently patients at increased risk of relapse. No significant financial relationships to disclose.